DoubleTwist, Inc. (genomic research company)

MSRP: $199.95
(You save $30.00 )
(No reviews yet) Write a Review
Gift wrapping:
Options available in Checkout
Adding to cart… The item has been added
Beautifully engraved specimen certificate from the DoubleTwist, Inc. . This historic document was printed by the Banknote Corporation of America and has an ornate border around it with a vignette of a DNA molecule. This item has the printed signatures of the company's president/ceo and secretary. DoubleTwist, Inc. is a leading provider of genomic information and bioinformatics analysis technologies. The company provides research environments that leverage information technology and the World Wide Web to simplify and accelerate genomic research. DoubleTwist was originally founded in 1993 as Pangea Systems, Inc., the first company to provide enterprise-scalable bioinformatics software applications. The company established a variety of collaborations and software license agreements with leading biotechnology and pharmaceutical companies, as well as business alliances with Sun Microsystems and Oracle. DoubleTwist received its first round of venture funding in 1997 from Mayfield Fund, Institutional Venture Partners, and Kleiner Perkins Caufield & Byers. In December 1999, Pangea Systems was re-launched as DoubleTwist. The change reflects a new focus on the portal. The company's data warehousing, processing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist also sells components of the portal to life sciences research organizations that are interested in building their own large-scale solutions for genomic research and discovery. DoubleTwist has raised $73 million from Mayfield Fund, Institutional Venture Partners, Kleiner Perkins Caufield & Byers, MDS Capital Corp., Boston Millennia Partners, Levensohn Capital Management, Moss Forest Ventures, The Burrill Agbio Capital Fund, Mitsui & Co. (U.S.A.), Inc., MPM Asset Management, T. Rowe Price, the INVESCO Global Health Sciences Fund, Lone Pine Capital LLC, and Amerindo Investment Advisors.